Transporting Antitumor Drug Tamoxifen and Its Metabolites, 4-Hydroxytamoxifen and Endoxifen by Chitosan Nanoparticles

Daniel Agudelo¹, Sriwanna Sanyakamdhorn¹, Shoher Nafisi², Heidar-Ali Tajmir-Riahi¹∗

¹ Department of Chemistry-Biology, University of Quebec at Trois-Rivières, Trois-Rivieres, Quebec, Canada, ² Department of Chemistry, San Jose State University, San Jose, California, United States of America

Abstract

Synthetic and natural polymers are often used as drug delivery systems in vitro and in vivo. Biodegradable chitosan of different sizes were used to encapsulate antitumor drug tamoxifen (Tam) and its metabolites 4-hydroxytamoxifen (4-Hydroxytam) and endoxifen (Endox). The interactions of tamoxifen and its metabolites with chitosan 15, 100 and 200 KD were investigated in aqueous solution, using FTIR, fluorescence spectroscopic methods and molecular modeling. The structural analysis showed that tamoxifen and its metabolites bind chitosan via both hydrophilic and hydrophobic contacts with overall binding constants of $K_{\text{tam-ch-15}} = 8.7 \pm 0.5 \times 10^5 \text{ M}^{-1}$, $K_{\text{tam-ch-100}} = 5.9 \pm 0.4 \times 10^5 \text{ M}^{-1}$, $K_{\text{tam-ch-200}} = 2.4 \pm 0.4 \times 10^5 \text{ M}^{-1}$ and $K_{\text{hydroxytam-ch-15}} = 2.6 \pm 0.3 \times 10^5 \text{ M}^{-1}$, $K_{\text{hydroxytam-ch-100}} = 5.2 \pm 0.7 \times 10^5 \text{ M}^{-1}$ and $K_{\text{hydroxytam-ch-200}} = 4.1 \pm 0.4 \times 10^5 \text{ M}^{-1}$, $K_{\text{endox-ch-15}} = 1.2 \pm 0.3 \times 10^5 \text{ M}^{-1}$ and $K_{\text{endox-ch-200}} = 4.7 \pm 0.5 \times 10^5 \text{ M}^{-1}$ with the number of drug molecules bound per chitosan (n) 2.8 to 0.5. The order of binding is c-h100>c200>c15 KD with stronger complexes formed with 4-hydroxytamoxifen than tamoxifen and endoxifen. The molecular modeling showed the participation of polymer charged NH2 residues with drug OH and NH2 groups in the drug-polymer adducts. The free binding energies of $-3.46 \text{ kcal/mol}$ for tamoxifen, $-3.54 \text{ kcal/mol}$ for 4-hydroxytamoxifen and $-3.47 \text{ kcal/mol}$ for endoxifen were estimated for these drug-polymer complexes. The results show chitosan 100 KD is stronger carrier for drug delivery than chitosan-15 and chitosan-200 KD.

Introduction

The nonsteroid antiestrogen tamoxifen [trans-1-(4-β-dimethlamo-noethoxy-phenyl)-1,2-diphenylbut-1-ene] (Fig. 1) is the most commonly used endocrine treatment for estrogen receptor α (ERα)-positive breast cancer in pre- and post-menopausal women, and it has helped to reduce breast cancer death rate by one third [1–3]. It is also used for the prevention of breast cancer in women at high risk of developing the disease [3]. In addition, it is used for the treatment of male breast cancer [4]. Although aromatase inhibitors are currently available for breast cancer treatment in postmenopausal women, tamoxifen is still the “gold standard” of breast cancer therapy because it is cost effective, life saving and is devoid of major adverse side effects in the majority of patients [5,6]. Tamoxifen is extensively metabolized, and several metabolites have been detected in human serum [7–9]. It is metabolized to 4-hydroxytamoxifen and N-desmethyltamoxifen by the action of CYP2D6 and CYP3A4/5 enzymes, respectively. N-desmethyltamoxifen and 4-hydroxy-tamoxifen are further converted to endoxifen (Fig. 1) by the action of CYP2D6 and CYP3A4/5, respectively [10–12]. The therapeutic efficacy of tamoxifen is determined by the distribution of the drug into tissues and the availability of the parent drug and its active metabolites in target tissues. However, effective transportation of tamoxifen and its metabolites to target molecules has to be improved and synthetic and natural biopolymers can be used as delivery tools for drug encapsulation.

Chitosan (Fig. 1) is a natural polymer obtained by deacetylation of chitin [13]. It is non-toxic, biocompatible and biodegradable polysaccharide. Chitosan nanoparticles have gained more attention as drug delivery carriers because of their better stability, low toxicity, simple and mild preparation method and providing versatile routes of administration [13–17]. The deacetylated chitosan backbone of glucosamine units has a high density of charged amine groups, permitting strong electrostatic interactions with proteins and genes that carry an overall negative charge at neutral pH conditions [13,14]. The fast expanding research of the useful physicochemical and biological properties of chitosan has led to the recognition of the cationic polysaccharide, as a natural polymer for drug delivery [17–20]. Therefore it is of a major interest to study the encapsulation of tamoxifen and its metabolites with chitosan of different sizes, in order to evaluate the efficacy of chitosan nanoparticles in drug delivery.

Fluorescence quenching is considered as a useful and reliable method for measuring binding affinities [21]. Fluorescence quenching is the decrease of the quantum yield of fluorescence...
from a fluorophore induced by a variety of molecular interactions with quencher molecule [22]. Therefore, it is possible to use quenching of the tamoxifen, 4-hydroxytamoxifen and endoxifen molecules in an attempt to characterize the nature of drug-chitosan interaction. Molecular docking is also an important tool to predict the binding sites of tamoxifen, 4-hydroxytamoxifen and endoxifen with chitosan nanoparticles.

The spectroscopic analysis and docking studies of the encapsulation of tamoxifen, 4-hydroxytamoxifen and endoxifen by chitosan nanoparticles 15, 100 and 200 KD in acetate solution at pH 5.5–6.5, using constant polymer concentration and various drug contents are reported. The structural analysis regarding drug binding sites, the effect of chitosan sizes on the stability of drug-polymer complexes and the efficacy of chitosan nanoparticles in drug delivery are discussed here.

Materials and Methods

Materials
Purified chitosans 15, 100 and 200 KD (90% deacetylation) were from Polysciences Inc. (Warrington, USA) and used as supplied. Tamoxifen and 4-hydroxytamoxifen were from Sigma Chemical Company. The synthesis of endoxifen was conducted as reported [23]. Other chemicals were of reagent grade and used without further purification.

Preparation of stock solutions
An appropriate amount of chitosan was dissolved in acetate solution (pH 5.5–6.5). The Drug solutions (1 mM) tamoxifen and its metabolites in ethanol/water (25/75%) were prepared and then diluted by serial dilution in acetate buffer.

FTIR spectroscopic measurements
Infrared spectra were recorded on a FTIR spectrometer (Impact 420 model, Digilab), equipped with deuterated triglycerine sulphate (DTGS) detector and KBr beam splitter, using AgBr windows. Solution of drug was added dropwise to the chitosan solution with constant stirring to ensure the formation of homogeneous solution and to reach the target drug concentrations of 15, 30 and 60 µM with a final chitosan concentration of 60 mM. Spectra were collected after 2 h incubation of chitosan with drug solution at room temperature, using hydrated films. Interferograms were accumulated over the spectral range 4000–600 cm\(^{-1}\) with a nominal resolution of 2 cm\(^{-1}\) and 100 scans. The difference spectra [(chitosan solution + drug solution) – (chitosan solution)] were generated using free chitosan band around 902 cm\(^{-1}\); as standard. This band is related to chitosan ring stretching [20,24,25] and does not show alterations upon drug complexation. When producing difference spectra, this band was adjusted to the baseline level, in order to normalize the difference spectra.
Fluorimetric experiments were carried out on a Perkin-Elmer LS55 Spectrometer. Stock solution of drug (30 \( \text{mM} \)) in acetate (pH 5.5–6.5) was also prepared at 24 \( \pm 1 \)°C. Various solutions of chitosan (1 to 200 \( \text{mM} \)) were prepared from the above stock solutions by successive dilutions at 24 \( \pm 1 \)°C. Samples containing 0.06 ml of the above drug solution and various polymer solutions were mixed to obtain final chitosan concentrations ranging from 1 to 200 \( \text{mM} \) with constant drug content (30 \( \text{mM} \)). The fluorescence spectra were recorded at \( \lambda_{\text{ex}} = 270–290 \) nm and \( \lambda_{\text{em}} \) from 300 to 450 nm. The intensity of the band at 375 nm from tamoxifen and its metabolites [26] was used to calculate the binding constant (K) according to previous reports [27–32].

On the assumption that there are \( n \) substantive binding sites for drug \( (Q) \) on polymer \( (B) \), the quenching reaction can be shown as follows:

\[
nQ + B \rightarrow Q_nB
\]  

(1)

Figure 2. FTIR spectra in the region of 1800–600 cm\(^{-1}\) of hydrated films (pH 6) for free chitosan (60 \( \mu \text{M} \)) and its tamoxifen complexes for (A) chitosan-15 KD, (B) chitosan-100 KD and (C) chitosan-200 KD with difference spectra (diff.) (bottom two curves) obtained at different drug concentrations (indicated on the figure).

doi:10.1371/journal.pone.0060250.g002
The binding constant \( K_A \) can be calculated as:

\[
K_A = \frac{[Q_nB]_n}{[Q]^n[B]}
\]  

where, \([Q]\) and \([B]\) are the drug and polymer concentration, respectively, \([Q_nB]_n\) is the concentration of non fluorescent fluorophore-drug complex and \([B_0]\) gives total polymer concentration:

\[
[B]_0 = [B] + [Q_nB]_n
\]

The fluorescence intensity is proportional to the polymer concentration as described:

\[
\frac{[B]}{[B_0]} \propto F/F_0
\]
Results from fluorescence measurements can be used to estimate the binding constant of drug-polymer complex. From eq 4:

\[
\log \left( \frac{F_0 - F}{F} \right) = \log K_A + \log [Q] \tag{6}
\]

The accessible fluorophore fraction \( f \) can be calculated by modified Stern-Volmer equation:

\[
\frac{F_0}{F_0 - F} = \frac{1}{f} K \cdot [Q] + \frac{1}{f} \tag{7}
\]

where, \( F_0 \) is the initial fluorescence intensity and \( F \) is the fluorescence intensities in the presence of quenching agent (or interacting molecule). \( K \) is the Stern-Volmer quenching constant, \([Q]\) is the molar concentration of quencher and \( f \) is the fraction of accessible fluorophore to a polar quencher, which indicates the fractional fluorescence contribution of the total emission for an interaction with a hydrophobic quencher [21,22]. The \( K \) will be calculated from \( F_0/F = K [Q] + 1 \).

**Molecular modeling.** The docking studies were carried out with ArgusLab 4.0.1 software (Mark A. Thompson, Planaria Software LLC, Seattle, Wa, http://www.arguslab.com). The chitosan structure was obtained from literature report [33] and

![Figure 4. FTIR spectra in the region of 1800–600 cm\(^{-1}\) of hydrated films (pH 6) for free chitosan (60 \( \mu M \)) and its endoxifen complexes for (A) chitosan-15 KD, (B) chitosan-100 KD and (C) chitosan-200 KD with difference spectra (diff.) (bottom two curves) obtained at different drug concentrations (indicated on the figure).](doi:10.1371/journal.pone.0060250.g004)
the drug three dimensional structures were generated from PM3 semi-empirical calculations using Chem3D Ultra 11.0. The whole polymer was selected as a potential binding site, since no prior knowledge of such site was available in the literature (Modeling ref.). The docking runs were performed on the ArgusDock docking engine using regular precision with a maximum of 150 candidate poses. The conformations were ranked using the Ascore scoring function, which estimates the free binding energy. Upon location of the potential binding sites, the docked complex conformations were optimized using a steepest decent algorithm until convergence, with a maximum of 20 iterations. Chitosan donor groups within a distance of 3.5 Å [34] relative to the drug were involved in complex formation.

Results and Discussion

FTIR spectra of drug-chitosan complexes

The drug-chitosan interactions were characterized by infrared spectroscopy and its various modifications. The shifting and intensity variations of the chitosan amide I band at 1637–1632 cm⁻¹ (mainly C = O stretch) and amide II band at 1540–1526 cm⁻¹ (C–N stretching coupled with N-H bending modes) [20,24,25] were monitored, upon drug interaction. The shift in the polymer amide I and amide II bands and the polymer OH stretching at 3500–3400 cm⁻¹ and N-H stretching mode at 3300–3200 cm⁻¹, upon drug complexation that will be discussed further on.

As drug concentration increased (30 to 60 μM), a major increase in the intensity of the polymer amide I and amide II vibrations as well as other frequencies was observed with positive features at 1633–1625 (tamox-ch-15), 1656–1632 (tamox-ch-100), 1633–1627 cm⁻¹ (4-hydroxytamox-ch-15) and 1633–1627 cm⁻¹ (4-hydroxytamox-ch-100) and 1656–1632 (endox-ch-15), 1654–1632 (endox-ch-100) and 1654–1624 (endox-ch-200) in the spectra of drug-chitosan complexes (Figs 2, 3 and 4, complex, 60 μM). In addition, the polymer amide I and amide II bands exhibited major shifting upon drug complexation (Figs. 2, 3 and 4, complex). The major shifting and increase in the intensity of the amide I band in the spectra of the drug-polymer complexes suggests a further interaction of drug with chitosan polar groups.

Figure 5. FTIR spectra in the region of 3500–2800 cm⁻¹ of hydrated films (pH 6.0) for free chitosan and their tamox, 4-hydroxytamox and endoxifen complexes obtained with 60 μM polymer and 60 μM drug concentrations.

doi:10.1371/journal.pone.0060250.g005
Analysis of the infrared spectra of chitosan in the region of 3500–2800 cm\(^{-1}\) showed major shifting of polymer OH, NH and CH stretching modes (Fig. 5) [24,25]. The polymer OH stretching vibrations at 3415, 3356 (free ch-15), 3418, 3359 (free ch-100) and 3419, 3359 cm\(^{-1}\) (free ch-200) showed major shifting and intensity changes, in the spectra of tamoxifen and its metabolite complexes (Fig. 5). Similarly, the NH stretching vibrations at 3198 (free ch-15), 3273 (free-ch-100) and 3271 cm\(^{-1}\) (free ch-200) exhibit major shifting upon drug complexation (Fig. 5). The spectral changes of the polymer OH and NH stretching modes are due to the participation of chitosan OH and NH\(_2\) group in drug-polymer complexes (hydrophilic contacts). However, the shifting of the polymer symmetric and antisymmetric CH stretching vibrations observed for 2920, 2851 (free ch-15), 2919, 2853 (free ch-100) and 2919, 2851 (free ch-200) in the spectra of tamoxifen, 4-hydroxytamoxifen and endoxifen-polymer complexes is related to the hydrophobic contacts in the drug-chitosan complexes (Fig. 5). The overall spectral changes observed in this region 3500–2800 cm\(^{-1}\) are due to the presence of both hydrophilic and hydrophobic contacts, in the drug-chitosan complexes.

Fluorescence spectra and stability of drug-chitosan complexes

Since chitosan is a weak fluorophore, the titrations of tamoxifen, 4-hydroxytamoxifen and endoxifen-polymer complexes are related to the hydrophobic contacts in the drug-chitosan complexes (Fig. 5). The overall spectral changes observed in this region 3500–2800 cm\(^{-1}\) are due to the presence of both hydrophilic and hydrophobic contacts, in the drug-chitosan complexes.

Fluorescence spectra and stability of drug-chitosan complexes

Since chitosan is a weak fluorophore, the titrations of tamoxifen, 4-hydroxytamoxifen and endoxifen were done against various polymer concentrations, using drug excitation at 270–290 nm and emission at 350–450 nm [26]. When drug interacts with chitosan, drug fluorescence may change depending on the impact of such interaction on the drug conformation, or via direct quenching effect. The decrease of fluorescence intensity of tamoxifen, 4-hydroxytamoxifen or endoxifen has been monitored at 375 nm for Figure 6. Fluorescence emission spectra of drug-chitosan systems in 10 mM acetate buffer pH 6 at 25°C presented for (A) tam-ch-15: (a) free tam (30 μM), (b-f) with chitosan at 30, 40, 50, 60, 80 and 100 μM; (B) tam-chitosan-100: (a) free tam (30 μM), (b-h) chitosan at 1, 3, 5, 7, 10, 15, 20 and 30 μM; (C) tam-ch-200: (a) free tam (30 ) (b-f) with chitosan at 3, 5, 7, 20 and 30, μM; Inset: K values calculated by $F_0/(F_0 - A)$ vs 1/[chitosan] for A’ (tam-chitosan-15), B’ (tam-chitosan 100) and C’ (tam-chitosan-200).

doi:10.1371/journal.pone.0060250.g006

Figure 7. Fluorescence emission spectra of drug-chitosan systems in 10 mM acetate buffer pH 6 at 25°C presented for (A) 4-hydroxytam-ch-15: (a) free 4-hydroxytam (30 μM), (b-h) with chitosan at 30, 40, 50, 60, 80, 100, 120 and 140 μM; (B) 4-hydroxytam-chitosan-100: (a) free 4-hydroxytam (30 μM), (b-h) chitosan at 1, 3, 5, 7, 10, 15, 20 and 30 μM; (C) 4-hydroxytam-ch-200: (a) free 4-hydroxytam (30 ) (b-f) with chitosan at 3, 5, 7, 20 and 30 μM; Inset: K values calculated by $F_0/(F_0 - A)$ vs 1/[chitosan] for A’ (4-hydroxytam-chitosan-15), B’ (4-hydroxytam-chitosan 100) and C’ (4-hydroxytam-chitosan-200).

2919, 2851 (free ch-200) in the spectra of tamoxifen, 4-hydroxytamoxifen and endoxifen-polymer complexes is related to the hydrophobic contacts in the drug-chitosan complexes (Fig. 5). The overall spectral changes observed in this region 3500–2800 cm\(^{-1}\) are due to the presence of both hydrophilic and hydrophobic contacts, in the drug-chitosan complexes.
quenching constant can be taken as the binding constant of the complex formation. The $K$ value given here averages four and six-replicate run for drug-polymer systems. Each run involves several different concentrations of chitosan (Figs 6A–C, 7A–C and 8A–C).

The overall binding constants were $K_{\text{Tam-ch-15}} = 8.7 \pm 0.5 \times 10^{3}$ M$^{-1}$, $K_{\text{Tam-ch-100}} = 5.9 \pm 0.4 \times 10^{3}$ M$^{-1}$, $K_{\text{Tam-ch-200}} = 2.4 \pm (0.4) \times 10^{3}$ M$^{-1}$ and $K_{\text{Endox-chitosan-15}} = 2.6 \pm (0.3) \times 10^{4}$ M$^{-1}$; $K_{\text{Hydroxytam-ch-100}} = 5.2 \pm (0.7) \times 10^{5}$ M$^{-1}$ and $K_{\text{Hydroxytam-ch-200}} = 5.1 \pm (0.5) \times 10^{5}$ M$^{-1}$, $K_{\text{Endox-ch-100}} = 1.2 \pm (0.3) \times 10^{5}$ M$^{-1}$ and $K_{\text{Endox-ch-200}} = 4.7 \pm (0.5) \times 10^{5}$ M$^{-1}$ (Figs 6A–C, 7A–C and 8A–C and Table 1). The order of binding constants calculated for the drug-chitosan adducts, showed ch-100 > 200 > 15 KD with more stable complexes formed with 4-hydroxytamoxifen than tamoxifen and endoxifen (Table 1). It is important to note that ch-15 is smaller than ch-100 and ch-200, while drug-interaction is mainly via positively charged drug-chitosan complexes indicating a large portion of fluorophore was exposed to quencher.

The number of drug molecules bound per polymer ($n$) is calculated from log $([F_0/F] = \log K_S + n \log [\text{chitosan}])$ for the static quenching [20,35–38]. The $n$ values from the slope of the straight line plot showed 0.5 to 2.8 drug molecules that are bound per chitosan molecule (Fig. 9 and Table 1). The results indicate some degree of cooperativity for drug-polymer interaction. In order to verify the presence of static or dynamic quenching in drug-chitosan complexes we have plotted $F_0/F$ versus $[Q]$ to estimate the quenching constant ($K_Q$) and the results are shown in Fig. 10. The plot of $F_0/F$ versus $[Q]$ is a straight line for drug-chitosan adducts indicating that the quenching is mainly static in these drug-polymer complexes (Fig. 10). The quenching constant $K_Q$ was estimated according to the Stern-Volmer equation:

$$F_0/F = 1 + k_{Q}[Q] = 1 + K_Q[Q]$$

where $F_0$ and $F$ are the fluorescence intensities in the absence and presence of quencher, $[Q]$ is the quencher concentration and $K_Q$ is the Stern-Volmer quenching constant [39] which can be written as $K_{sv} = k_{Q}G_0$; where $k_{sv}$ is the bimolecular quenching rate constant.

---

**Figure 8.** Fluorescence emission spectra of drug-chitosan systems in 10 mM acetate buffer pH 6 at 25°C presented for (A) endox-ch-15: (a) free endox (30 µM), (b–i) chitosan at 30, 40, 50, 60, 80, 100, 120, 140 and 160 µM; (B) endox-chitosan-100: (a) free endox (30 µM), (b–h) chitosan at 1, 3, 5, 7, 10, 15, 20 and 30 µM; (C) endox-ch-200: (a) free endox (30) (b–g) with chitosan at 3, 5, 7, 10, 20 and 30 µM; Inset: $K$ values calculated by $F_0/(F_0 – F)$ vs 1/[chitosan] for A’ (endox-chitosan-15), B’ (endox-chitosan 100) and C’ (endox-chitosan-200). doi:10.1371/journal.pone.0060250.g008

**Table 1.** Binding parameters for drug-chitosan complexes.

| Complexes | $K_	ext{sv}$ (M$^{-1}$) | $K_	ext{n}$ (M$^{-1}$) | n | $K_	ext{Q}$ (M$^{-1}$ s$^{-1}$) |
|-----------|-----------------|-----------------|---|-----------------|
|           | Ch-15 | Ch-100 | Ch-200 | Ch-15 | Ch-100 | Ch-200 | Ch-15 | Ch-100 | Ch-200 | Ch-15 | Ch-100 | Ch-200 |
| Tamox | 6.8 $\times 10^7$ | 5.4 $\times 10^6$ | 8.5 $\times 10^5$ | 8.7 $\times 10^5$ | 5.9 $\times 10^5$ | 2.4 $\times 10^5$ | 1.5 | 2.8 | 0.9 | 3.2 $\times 10^{16}$ | 2.6 $\times 10^{15}$ | 4.0 $\times 10^{16}$ |
| Hydroxytam | 1.8 $\times 10^8$ | 6.3 $\times 10^7$ | 4.4 $\times 10^6$ | 2.6 $\times 10^6$ | 5.1 $\times 10^5$ | 5.1 $\times 10^5$ | 1.3 | 0.6 | 0.7 | 8.5 $\times 10^{16}$ | 3.0 $\times 10^{16}$ | 2.1 $\times 10^{17}$ |
| Endox | 5.8 $\times 10^7$ | 5.2 $\times 10^6$ | 1.7 $\times 10^5$ | 4.1 $\times 10^5$ | 1.2 $\times 10^5$ | 4.7 $\times 10^5$ | 1.2 | 0.5 | 0.5 | 2.7 $\times 10^{16}$ | 2.4 $\times 10^{16}$ | 7.9 $\times 10^{16}$ |

doi:10.1371/journal.pone.0060250.t001

PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e60250
Figure 9. Stern-Volmer plots of fluorescence quenching constant ($K_Q$) for the chitosans and their drug complexes at different chitosan concentrations.
doi:10.1371/journal.pone.0060250.g009

Figure 10. The plot of Log ($[F_0-F]/F$) as a function of Log (chitosan concentrations) for the number of bound drug molecules per chitosan ($n$) for drug-polymer complexes.
doi:10.1371/journal.pone.0060250.g010
and $t_0$ is the lifetime of the fluorophore in the absence of quencher ($\tau_0$ is the lifetime of the fluorophore in the absence of quencher complexes.

Figure 11. Best docked conformations of drug–chitosan complexes. (A) for tamoxifen bound to chitosan and (B) for 4-hydroxytamoxifen bound to chitosan (C) for endoxifen bound to chitosan with free binding energy.

doi:10.1371/journal.pone.0060250.g011

$10.6 \times 10^{16} M^{-1}/s$ for 4-hydroxytamox-ch-15, $2.1 \times 10^{16} M^{-1}/s$ for 4-hydroxytamox-ch-100, $2.7 \times 10^{16} M^{-1}/s$ for endox-ch-15, $2.4 \times 10^{16} M^{-1}/s$ for endox-ch-100 and, $7.9 \times 10^{16} M^{-1}/s$ for endox-ch-200 (Fig. 10 and Table 1). Since these values are much greater than the maximum collisional quenching constant ($2.0 \times 10^{10} M^{-1}/s$), the static quenching is dominant in these drug-polymer complexes [39].

Docking

The spectroscopic data were combined with docking experiments in which tamoxifen, 4-hydroxytamoxifen and endoxifen molecules were docked to chitosan to determine the preferred binding sites on the chitosan. The models of the docking for drug are shown in Fig. 11. The docking results showed that tamoxifen and its metabolites are surrounded by several donor atoms of chitosan residue on the surface with a free binding energy of $-3.46 \text{ kcal/mol for tamox-chitosan}$ $-3.54 \text{ kcal/mol for 4-hydroxytamox-chitosan}$ and $-3.47 \text{ kcal/mol for endoxifen-chitosan}$ complexes (Fig. 11). It is evident that tamoxifen and its metabolites are not surrounded by similar donor groups showing different binding modes, in these drug-chitosan complexes with more stable adducts formed for 4-hydroxytamoxifen, which is consistent with our spectroscopic results (Fig 11 and Table 1).

Conclusion

The spectroscopic and docking results presented here show that tamoxifen and its metabolites bind chitosan via different binding modes. Major hydrophobic and hydrophilic interactions via chitosan charged NH$_2$ groups are observed in these drug-polymer complexes. The order of drug-chitosan binding is ch-100>ch-200>ch-15. Stronger complexes formed for 4-hydroxytamoxifen due to more hydrophilic and hydrophobic characters. Chitosan-100 KD is a stronger carrier for tamoxifen and its metabolites than chitosan 15 and chitosan 100 KD for drug delivery in vitro.

Author Contributions

Conceived and designed the experiments: DA SS. Performed the experiments: DA SS. Analyzed the data: DA SS. Contributed reagents/materials/analysis tools: SN. Wrote the paper: HATR.

References

1. Jordan V C (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 147 Suppl: S269–S276.
2. Spears M, Bartlett J (2009) The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer. Expert Opin Ther Targets 13: 665–674.
3. Brausch J, Jordan VC (2009) Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer. Eur J Cancer 45: 2274–2283.
4. Hayes T G (2009) Pharmacologic treatment of male breast cancer. Expert Opin Pharmacother 10: 2499–510.
5. Nabholtz J M, Gligorov J (2006) The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. Rev Recent Clin Trials 1: 237–249.
6. Jordan V C (2008) Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 44: 30–31.
7. Jordan V C (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72: 829–842.
8. Lien E A, Solheim E, Ueland P M (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51: 4937–4944.
9. Furlanet M, Franceschi L, Pasqual E, Bacchetti S, Poz D, et al. (2007) Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women. Ther Drug Monit 29: 349–352.
10. Hoskins J M, Carey L A, McLeod H L (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9: 576–586.
11. Schroth W, Goetz MP, Hamann U, Fasching P A, Schmidt M, et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302: 1429–1436.
12. Bijl M J, van Schaik R H, Lammers L A, Hofman A, Vulto AG, et al. (2009) The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 118: 125–130.
13. Pacheco N, Gamica-Gonzalez M, Gimeno M, Barzana E, Trombetta S, et al. (2011) Structural characterization of chitin and chitosan obtained by biological and chemical methods. Biomacromolecules 12: 3285–3290.
14. Kabea EI, Badasy MET, Stevens CV, Smaghe G, Steurbaut W (2003) Chitosan as antimicrobial agent: application and mode of action. Biomacromolecules 4: 1457–1465.
15. Dang J M, Leong KW (2006) Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev 58: 487–499.
16. Gan Q, Wang T (2007) Chitosan nanoparticles as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids Surfaces B. Biointerfaces 59: 24–34.
17. Mao S, Shuai X, Unger F, Simon M (2004) The depolymerization of chitosan: effects on physicochemical and biological properties. Int J Pharm 281: 45–54.
18. Saranya N, Moorthi A, Saravanan S, Pandiima Devi M, Selvanamugan N (2001) Chitosan and its derivatives for gene delivery. Int J Biol Macromol 28: 234–238.
19. Shu Z Z, Zhu K J (2009) A novel approach to prepare tripolyphosphate: chitosan complex beads for controlled release drug delivery. Int J Pharm 201: 51–56.
20. Sanyakamdhorn S, Agudelo D, Tajmir-Riahi H A (2013) Encapsulation of antitumor drug doxorubicin and its analogue by chitosan nanoparticles. Biomacromolecules 14: 557–563.

21. Lakowicz JR (2006) In Principles of fluorescence spectroscopy 3rd ed; Springer: New York.

22. Tayeh N, Rungassamy T, Albani JR (2009) Fluorescence spectral resolution of tryptophan residues in bovine and human serum albumins. J Pharm Biomed Anal 50: 107–116.

23. Faq A H, Maharvi GM, Sinha D (2010) A convenient synthesis of 3(Z)-4-hydroxy-N-desmethyltamoxifen (endoxifen). Bioorg Med Chem Lett 15: 3036–3038.

24. Brugarotto J, Lizardi J, Goycoolea F M, Arguelles-Monal W, Deshieres J, et al. (2008) An infrared investigation in relation with chitin and chitosan characterization. Polymer 49: 3569–3580.

25. Palpandi C, Shanmugam V, Shanmugam A (2009) Extraction of chitin and chitosan from shell and operculum of mangrove gastropod Nerita (Dostia) crepidularia Lamarck. Intl J Med Med Sci 1: 198–203.

26. Engelke M, Bjojarks P, Blob R, Died H (2001) Tamoxifen perturbs lipid bilayer order and permeability: comparison of DSC, fluorescence anisotropy, Laurdan generalized polarization and carboxyfluorescein leakage studies. Biophys Chem 90: 157–173.

27. Sarzehi S, Chamani J (2010) Investigation on the interaction between tamoxifen and human holo-tranferrin: determination of the binding mechanism by fluorescence quenching resonance light scattering and circular dichroism methods. Intl J Biol Macromol 47: 558–569.

28. Dufour C, Dangles O (2003) Flavonoid-serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy. Biochim Biophys Acta 1721: 164–173.

29. He W, Li Y, Xue C, Hu Z, Chen X, et al. (2005) Effect of Chinese medicine alpinetin on the structure of human serum albumin, Bioorg Med Chem 13: 1837–1845.

30. Iranfar H, Rajabi O, Salari R, Chamani J (2012) Probing the interaction of human serum albumin with ciprofloxacin in the presence of silver nanoparticles of three sizes: multispectroscopic and χ potential investigation. J Phys Chem B 116: 1951–1964.

31. Bi S, Ding L, Tian Y, Song D, Zhou X, et al. (2004) Investigation of the interaction between flavonoids and human serum albumin. J Mol Struct 703: 37–45.

32. Jiang M, Xie MX, Zheng D, Liu Y, Li XY, et al. (2004) Spectroscopic studies on the interaction of cinnamic acid and its hydroxyl derivatives with human serum albumin. J Mol Struct 692: 71–80.

33. Skovstrup S, Hansen S G, Skyrdstrup T, Schrott B (2010) Conformational flexibility of chitosan: a molecular modeling study. Biomacromolecules, 11: 3196–3207.

34. Manikrao AM, Mahajan NS, Jawarkar DR, Khatale PN, Kedar KC, et al. (2012) Thrombare: Docking analysis of darunavir as HIV protease inhibitors. J Comput Methods Mol Design 2012, 2: 29–43.

35. Maneville JS, Tajmir-Riahi HA (2010) Complexes of dendrimers with bovine serum albumin. Biomacromolecules 11: 465–472.

36. Charbonneau DM, Tajmir-Riahi H A (2010) Study on the interaction of cationic lipids with bovine serum albumin. J Phys Chem B 114: 1148–1155.

37. Boursara P, Kanakis DC, Taramilis P, Polissiou MG, Tajmir-Riahi HA (2010) Resveratrol, genistein and curcumin bind bovine serum albumin. J Phys Chem B 114: 3348–3354.

38. Froehlich E, Jennings JC, Sedaghat-Hezati MR, Tajmir-Riahi HA (2009) Dendrimers bind human serum albumin. J Phys Chem B 113: 6986–6993.

39. Zhang G, Que Q, Pan J, Guo J (2008) Study of the interaction between icariin and human serum albumin by fluorescence spectroscopy. J Mol Struct 881: 132–138.

40. Huang DC, Piche M, Ma G, Jean-Jacques M, Mario Khayat M (2010) Early detection and treatment monitoring of human breast cancer MCF-7 using fluorescence imaging. ART Advanced Research Technologies Inc.www.art.ca/docs/publications/WMIC2010_MCF7.pdf.